These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 8531240)

  • 1. Design and evaluation of rodent carcinogenicity studies (bioassay).
    Usui T
    J Toxicol Sci; 1995 Sep; 20(4):457-8. PubMed ID: 8531240
    [No Abstract]   [Full Text] [Related]  

  • 2. Long- and medium-term carcinogenicity studies in animals and short-term genotoxicity tests.
    Feron VJ; Schwarz M; Hemminki K; Krewski D
    IARC Sci Publ; 1999; (131):103-29. PubMed ID: 10505295
    [No Abstract]   [Full Text] [Related]  

  • 3. Review of alternative methods of carcinogenicity testing and evaluation of human pharmaceuticals.
    Van Deun K; Van Cauteren H; Vandenberghe J; Canning M; Vanparys P; Coussement W
    Adverse Drug React Toxicol Rev; 1997 Nov; 16(4):215-33. PubMed ID: 9608857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioassay design and MTD setting: old methods and new approaches.
    Swenberg JA
    Regul Toxicol Pharmacol; 1995 Feb; 21(1):44-51; discussion 81-6. PubMed ID: 7784635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the ability of a battery of three in vitro genotoxicity tests to discriminate rodent carcinogens and non-carcinogens II. Further analysis of mammalian cell results, relative predictivity and tumour profiles.
    Kirkland D; Aardema M; Müller L; Makoto H
    Mutat Res; 2006 Sep; 608(1):29-42. PubMed ID: 16769241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alternatives to the carcinogenicity bioassay: in silico methods, and the in vitro and in vivo mutagenicity assays.
    Benigni R; Bossa C; Tcheremenskaia O; Giuliani A
    Expert Opin Drug Metab Toxicol; 2010 Jul; 6(7):809-19. PubMed ID: 20438313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Commentary on "Evaluation of possible carcinogenic risk to humans based on liver tumors in rodent assays: the two-year bioassay is no longer necessary".
    Long GG
    Toxicol Pathol; 2010 Apr; 38(3):502-5. PubMed ID: 20124495
    [No Abstract]   [Full Text] [Related]  

  • 8. Issues in the design and interpretation of chronic toxicity and carcinogenicity studies in rodents: approaches to dose selection.
    Rhomberg LR; Baetcke K; Blancato J; Bus J; Cohen S; Conolly R; Dixit R; Doe J; Ekelman K; Fenner-Crisp P; Harvey P; Hattis D; Jacobs A; Jacobson-Kram D; Lewandowski T; Liteplo R; Pelkonen O; Rice J; Somers D; Turturro A; West W; Olin S
    Crit Rev Toxicol; 2007; 37(9):729-837. PubMed ID: 17957539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medium-term bioassays in rats for rapid detection of the carcinogenic potential of chemicals.
    Shirai T; Hirose M; Ito N
    IARC Sci Publ; 1999; (146):251-72. PubMed ID: 10353390
    [No Abstract]   [Full Text] [Related]  

  • 10. Accelerated rodent bioassay predictive of chemical carcinogenesis.
    Iatropoulos MJ
    Exp Toxicol Pathol; 1992 Dec; 44(8):481-7. PubMed ID: 1493367
    [No Abstract]   [Full Text] [Related]  

  • 11. Comments on the medium-term rat liver focus bioassay.
    Maronpot RR
    Toxicol Pathol; 1997; 25(5):461. PubMed ID: 9323834
    [No Abstract]   [Full Text] [Related]  

  • 12. The in vivo rodent test systems for assessment of carcinogenic potential.
    van der Laan JW; Spindler P
    Regul Toxicol Pharmacol; 2002 Feb; 35(1):122-5. PubMed ID: 11846641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Are tumor incidence rates from chronic bioassays telling us what we need to know about carcinogens?
    Gaylor DW
    Regul Toxicol Pharmacol; 2005 Mar; 41(2):128-33. PubMed ID: 15698536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of non-mammalian species in bioassays for carcinogenicity.
    Bunton TE
    IARC Sci Publ; 1999; (146):151-84. PubMed ID: 10353387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neonatal mouse assay for tumorigenicity: alternative to the chronic rodent bioassay.
    Flammang TJ; Tungeln LS; Kadlubar FF; Fu PP
    Regul Toxicol Pharmacol; 1997 Oct; 26(2):230-40. PubMed ID: 9356286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improving the power of long term rodent carcinogenicity bioassays by adjusting the experimental design.
    Jackson MT
    Regul Toxicol Pharmacol; 2015 Jul; 72(2):231-43. PubMed ID: 25908510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Historical review of the rodent bioassay and future directions.
    McConnell EE
    Regul Toxicol Pharmacol; 1995 Feb; 21(1):38-43; discussion 81-6. PubMed ID: 7784634
    [No Abstract]   [Full Text] [Related]  

  • 18. NTP announces bioassay results.
    Wolfe MS
    Environ Health Perspect; 2001 Aug; 109(8):A369. PubMed ID: 11564635
    [No Abstract]   [Full Text] [Related]  

  • 19. A review of evidence from short-term studies leading to the prediction that diazoaminobenzene (1,3-diphenyltriazine) is a carcinogen.
    Bordelon NR; Chhabra R; Bucher JR
    J Appl Toxicol; 2005; 25(6):514-21. PubMed ID: 16158390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IFSTP guidelines for the design and interpretation of the chronic rodent carcinogenicity bioassay.
    Faccini JM; Butler WR; Friedmann JC; Hess R; Reznik GK; Ito N; Hayashi Y; Williams GM
    Exp Toxicol Pathol; 1992 Dec; 44(8):443-56. PubMed ID: 1493363
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.